The enhancement of anti-tumor immune response and application to a therapy with the IDO inhibitor

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19584
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Hematology
• Research Institution: Nagoya City University
• Principal Investigator: Masaki Ayako 名古屋市立大学, 大学院医学研究科, 講師 (40648044)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: IDO / Malignant lymphoma / Tumor immunity

Outline of Final Research Achievements

Indoleamine 2,3-dioxygenase 1 (IDO) is one of enzyme catabolizing tryptophan into the kynurenine pathway, and recognized as an important microenvironmental factor suppressing antitumor immune responses. Quantification of serum Kyn and Trp is useful for predicting prognosis of an individual patients with hematological malignancy, such as adult T-cell leukemia/lymphoma, Hodgkin lymphoma, and follicular lymphoma. Furthermore, it is thought that IDO is an attractive novel cancer immunotherapies target in various hematological malignancy.

Free Research Field

造血器悪性腫瘍